Immune Memory: A New Frontier in Treating Recurrent Inflammatory Skin Diseases
- PMID: 40100550
- DOI: 10.1007/s12016-025-09039-0
Immune Memory: A New Frontier in Treating Recurrent Inflammatory Skin Diseases
Abstract
The recurrence of inflammatory skin diseases represents a significant challenge in clinical practice, primarily mediated by immune memory. In inflammatory skin diseases, immune memory encompasses adaptive immune memory, trained immunity, and inflammatory memory, which are conducted by adaptive immune cells, innate immune cells, and structural cells, respectively. Adaptive immune memory is established through gene rearrangement, leading to antigen-specific immune memory. In contrast, trained immunity and inflammatory memory are formed through epigenetic and metabolic reprogramming, resulting in non-specific immune memory. Different types of immune memory work synergistically to aggravate localized inflammation in recurrent inflammatory skin diseases. However, immune memory in specific cells, such as macrophages, may also play an immunoregulatory role under certain conditions. We reviewed the immune memory mechanisms in different inflammatory skin diseases and discussed future strategies for targeted regulation of the molecular mechanisms underlying immune memory, such as targeted biological agents and epigenetic modifications. Additionally, we explored the potential for precise regulation of immune memory and its application in personalized treatment for recurrent inflammatory skin diseases.
Keywords: Immune memory; Inflammatory memory; Inflammatory skin diseases; Trained immunity.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Competing Interests: The authors declare no competing interests.
References
-
- Picardo M, Dell’Anna ML, Ezzedine K, Hamzavi I, Harris JE, Parsad D, Taieb A (2015) Vitiligo. Nat Rev Dis Primer 1:15011. https://doi.org/10.1038/nrdp.2015.11 - DOI
-
- Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN (2021) Psoriasis. The Lancet 397:1301–1315. https://doi.org/10.1016/S0140-6736(20)32549-6 - DOI
-
- Chovatiya R, Paller AS (2021) JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol 148:927–940. https://doi.org/10.1016/j.jaci.2021.08.009 - DOI - PubMed - PMC
-
- Azzolino V, Zapata L, Garg M, Gjoni M, Riding RL, Strassner JP, Richmond JM, Harris JE (2021) Jak inhibitors reverse vitiligo in mice but do not deplete skin resident memory T cells. J Invest Dermatol 141:182-184.e1. https://doi.org/10.1016/j.jid.2020.04.027 - DOI - PubMed
-
- Lin CM, Cooles FA, Isaacs JD (2020) Basic mechanisms of JAK inhibition. Mediterr J Rheumatol 31:100–104. https://doi.org/10.31138/mjr.31.1.100 - DOI - PubMed - PMC
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
